LifeBond, a Caesarea Industrial Park, Israel-based developer of bio-surgical medical devices for tissue repair, closed a $27M Series D equity funding.
Participants in the round include Pitango Venture Capital, Adams Street Partners, Sino Biopharmaceutical Ltd., and all existing investors.
The company intends to use the funds for market introduction and commercialization in the European Union of its flagship product, the LifeSeal™ Surgical Sealant, the commencement and completion of an international, multi-center, pivotal study of LifeSeal to support FDA pre-market approval and the clinical development of its second pipeline product, LifeMesh™ self fixating mesh.
Led by CEO Mr. Gideon Sturlesi, LifeBond develops and manufactures bio-surgical medical devices for tissue repair intended to improve the recovery of patients following surgery and to create an environment that supports the body’s natural healing process. The company’s first product, LifeSeal™, is designed to provide staple-line reinforcement in GI surgery. It was recently studied in an international pilot clinical study in Europe and is now pending CE mark. Its second pipeline product, LifeMesh™, a self-fixating hernia mesh, is in pre-clinical development.
Other pipeline products include tissue adhesives and absorbable hemostats.
LifeSeal™, LifeMesh™ and other LifeBond products are investigational and have not yet been approved for sale in the US or in any other market.